Abstract
Randomized trials have established that the prophylactic use of implantable cardioverter–defibrillators (ICDs) prolongs survival in patients with left ventricular dysfunction that is due to myocardial infarction1 or associated with heart failure from any cause.2 One of the pivotal trials, the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) (ClinicalTrials.gov number, NC0609), compared ICD therapy or amiodarone with placebo in 2521 patients with symptomatic heart failure due to ischemic or nonischemic left ventricular dysfunction.2 That trial showed that among patients who had an ICD as compared with those who received a placebo, there was an absolute reduction in mortality of 7.2 . . .
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
